The new core drug and vaccine division, which CEO Emma Walmsley has dubbed "New GSK," has set targets of 5% sales growth and 10% profit growth between now and 2026.
The new core drug and vaccine division, which CEO Emma Walmsley has dubbed "New GSK," has set targets of 5% sales growth and 10% profit growth between now and 2026. The separation is expected to take effect in mid-2022. Investors have reacted positively to the plans thus far, with GSK shares up 3% by mid-afternoon trade in Europe.at the company's Capital Markets Day, having been under pressure of late from U.S. activist investor Elliott Management. The virtual session begins at 2 p.m. London time on Wednesday.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: